Keywords
Monoclonal antibodies
Efficacy
Drug-related side effects and adverse reactions
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: Review the efficacy and safety of the drug pembrolizumab in triple-negative breast cancer. Methods: An integrative review was carried out using the PUBMED, BVS, and LILACS databases, with the descriptors “pembrolizumab and triple negative breast cancer” and their alternative terms in Portuguese, English, and Spanish. The search was filtered for randomized clinical trials published in the last five years. Results: Nineteen articles were selected describing the safety and efficacy of pembrolizumab in TNBC. The drug showed better objective response rate (ORR), overall survival (OS), and progression-free survival (PFS) compared to chemotherapy alone. Regarding safety, grade 1 and 2 adverse events were reported, which may limit its use in patients with immune-related diseases. However, these effects were considered mild and manageable with corticosteroids and supportive care. Final considerations: Pembrolizumab is an effective and safe therapeutic alternative for the treatment of TNBC.
References
ADAMS S, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: Cohort A of the phase II KEYNOTE-086 study. Annals of Oncology 2019a; 30(3): 397–404.
ADAMS S, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: Cohort B of the phase II KEYNOTE-086 study. Annals of Oncology 2019b; 30(3): 405–11.
ANVISA. AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA. Keytruda® (pembrolizumabe): nova indicação [Internet]. [citado 2023 nov 13]; Available from: https ://www.gov.br/anvisa/pt-br/assuntos/medicamentos/novos-medicamentos-e-indicacoes/keytruda-r-pembrolizumabe-nova-indicacao-4.
ANDERS CK, et al. Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer. J Immunother Cancer, 2022; 10(2).
CHUN B, et al. Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer. J Immunother Cancer, 2022; 10(1).
CONITEC. Diretrizes diagnósticas terapêuticas: carcinoma de mama [Internet]. Brasília: Available from: https ://www.gov.br/conitec/pt-br. 2022.
CORTES J, et al. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. New England Journal of Medicine, 2022; 387(3): 217–26.
CORTES J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. The Lancet, 2020; 396(10265): 1817–28.
DERAKHSHAN F e REIS-FILHO JS. Pathogenesis of Triple-Negative Breast Cancer. Annual Review of Pathology: Mechanisms of Disease, 2021; 17: 181–204.
EGELSTON CA, et al. Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer. Cancer Immunology, Immunotherapy, 2023; 72(9): 3013–27.
EISENHAUER EA, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer, 2009; 45(2): 228–47.
FASCHING PA, et al. Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer – A single-arm phase II trial (NeoImmunoboost, AGO-B-041). Eur J Cancer, 2023; 184: 1–9.
HATTORI M, et al. Pembrolizumab plus chemotherapy in Japanese patients with triple-negative breast cancer: Results from KEYNOTE-355. Cancer Med, 2023; 12(9): 10280–93.
HO AY, et al. A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer. Cancer, 2020; 126(4): 850–60.
HUANG M, et al. Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic triple-negative breast cancer that expresses PD-L1. European Journal of Cancer, 2022; 177: 45–52.
INCA. INSTITUTO NACIONAL DO CÂNCER. Síntese de Resultados e Comentários [Internet]. Available from: https ://www.gov.br/inca/pt-br/assuntos/cancer/numeros/estimativa/sintese-de-resultados-e-comentarios. 2023.
MERCK SHARP & DOHME FARMACÊUTICA LTDA. KEYTRUDA ® [Internet]. Available from: https ://saude.msd.com.br/wp-content/uploads/sites/91/2022/12/keytruda_bula_pro.pdf. 2023.
MORRIS GJ, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and caucasian patients: a single-institution compilation compared with the National Cancer Institute’s surveillance, epidemiology, and end results database. Cancer, 2007; 110(4): 876–84.
OLADERU OT, et al. Association of Adjuvant Chemotherapy With Overall Survival Among Women With Small, Node-Negative, Triple-Negative Breast Cancer. JAMA Netw Open, 2020; 3(9): 2016247.
SCHMID P, et al. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. New England Journal of Medicine, 2022; 386(6): 556–67.
SCHMID P, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. New England Journal of Medicine, 2020a; 382(9): 810–21.
SCHMID P, et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. Annals of Oncology, 2020b; 31(5): 569–81.
SHAH M, et al. FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer. Clinical Cancer Research, 2022; 28(24): 5249–53.
TOLANEY SM, et al. Eribulin plus pembrolizumab in patients with metastatic triple-negative breast cancer (ENHANCE 1): A phase Ib/II study. Clinical Cancer Research, 2021; 27(11): 3061–8.
TOPALIAN SL, et al. Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell, 2015; 27(4): 450–61.
VASCONCELOS MC DE HV, et al. Evolução e desenvolvimento do tratamento farmacológico relativo ao câncer de mama triplo negativo: revisão integrativa. Research, Society and Development, 2023; 12(3): 6912340413.
VINAYAK S, et al. Open-label Clinical Trial of Niraparib Combined with Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. JAMA Oncol, 2019; 5(8): 1132–40.
WEBER JS, et al. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents. Oncologist, 2016; 21(10): 1230–40.
WINER E, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-199): a randomised, open-label, phase 3 trial. The Lancet Oncology, 2021; 22(4): 499–511.
XU J. Regulation of cancer immune checkpoints [Internet]. In: Advances in Experimental Medicine and Biology. Available from: http ://www.springer.com/series/5584. 2020.
YIN L, et al. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Research, 2020; 22(1).
YUAN Y, et al. A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer. Oncologist, 2021; 26(2): 99-217.